 |
|
Genetic Testing in an Ethnically Diverse Cohort of High-Risk Women
A Comparative Analysis of BRCA1 and BRCA2 Mutations in American Families of European and African Ancestry
Rita Nanda, MD;
L. Philip Schumm, MA;
Shelly Cummings, MS;
James D. Fackenthal, PhD;
Lise Sveen, MS;
Foluso Ademuyiwa, MD, MPH;
Melody Cobleigh, MD;
Laura Esserman, MD, MBA;
Noralane M. Lindor, MD;
Susan L. Neuhausen, PhD;
Olufunmilayo I. Olopade, MD
JAMA. 2005;294:1925-1933.
Context Ten years after BRCA1 and BRCA2 were first identified as major breast cancer susceptibility genes, the spectrum of mutations and modifiers of risk among many ethnic minorities remain undefined.
Objectives To characterize the clinical predictors, spectrum, and frequency of BRCA1 and BRCA2 mutations in an ethnically diverse high-risk clinic population and to evaluate the performance of the BRCAPRO statistical model in predicting the likelihood of a mutation.
Design, Setting, and Participants Comparative analysis of families (white, Ashkenazi Jewish, African American, Hispanic, Asian) with 2 or more cases of breast and/or ovarian cancer among first- and second-degree relatives. Families were identified at US sites between February 1992 and May 2003; in each family, the individual with the highest probability of being a mutation carrier was tested.
Main Outcome Measures Frequency of BRCA1 and BRCA2 mutations and area under the receiver operating characteristic curve for the BRCAPRO model.
Results The mutation spectrum was vastly different between families of African and European ancestry. Compared with non-Hispanic, non-Jewish whites, African Americans had a lower rate of deleterious BRCA1 and BRCA2 mutations but a higher rate of sequence variations (27.9% vs 46.2% and 44.2% vs 11.5%; P<.001 for overall comparison). Deleterious mutations in BRCA1 and BRCA2 were highest for Ashkenazi Jewish families (69.0%). Early age at diagnosis of breast cancer and number of first- and second-degree relatives with breast and ovarian cancer were significantly associated with an increased likelihood of carrying a BRCA1 or BRCA2 mutation. In discriminating between mutation carriers, BRCAPRO performed as well in African American families as it did in white and Jewish families, with an area under the curve of 0.77 (95% confidence interval, 0.61-0.88) for African American families and 0.70 (95% confidence interval, 0.60-0.79) for white and Jewish families combined.
Conclusions These data support the use of BRCAPRO and genetic testing for BRCA1 and BRCA2 mutations in the management of high-risk African American families. Irrespective of ancestry, early age at diagnosis and a family history of breast and ovarian cancer are the most powerful predictors of mutation status and should be used to guide clinical decision making.
Author Affiliations: Center for Clinical Cancer Genetics, Section of Hematology/Oncology, Department of Medicine (Drs Nanda, Fackenthal, Ademuyiwa, and Olopade and Mss Cummings and Sveen) and Department of Health Studies (Mr Schumm), University of Chicago Medical Center, Chicago, Ill; Rush Medical College, Chicago (Dr Cobleigh); University of California-San Francisco (Dr Esserman); Mayo Clinic, Rochester, Minn (Dr Lindor); and Division of Epidemiology, Department of Medicine, University of California-Irvine (Dr Neuhausen).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Genetic Variants of Uncertain Significance: Flies in the Ointment
Domchek and Weber
JCO 2008;26:16-17.
FULL TEXT
Prevalence of Pathogenic BRCA1 Mutation Carriers in 5 US Racial/Ethnic Groups
John et al.
JAMA 2007;298:2869-2876.
ABSTRACT
| FULL TEXT
BRCA1 and BRCA2 Genetic Testing in Hispanic Patients: Mutation Prevalence and Evaluation of the BRCAPRO Risk Assessment Model
Vogel et al.
JCO 2007;25:4635-4641.
ABSTRACT
| FULL TEXT
Validity of Models for Predicting BRCA1 and BRCA2 Mutations
Parmigiani et al.
ANN INTERN MED 2007;147:441-450.
ABSTRACT
| FULL TEXT
PancPRO: Risk Assessment for Individuals With a Family History of Pancreatic Cancer
Wang et al.
JCO 2007;25:1417-1422.
ABSTRACT
| FULL TEXT
Determination of Cancer Risk Associated with Germ Line BRCA1 Missense Variants by Functional Analysis
Carvalho et al.
Cancer Res. 2007;67:1494-1501.
ABSTRACT
| FULL TEXT
Sociocultural Predictors of Breast Cancer Risk Perceptions in African American Breast Cancer Survivors
Brewster et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:244-248.
ABSTRACT
| FULL TEXT
Mutations in Families at High Risk for Breast Cancer--Reply
Walsh et al.
JAMA 2006;296:2091-2092.
FULL TEXT
Prediction of germline mutations and cancer risk in the Lynch syndrome.
Chen et al.
JAMA 2006;296:1479-1487.
ABSTRACT
| FULL TEXT
Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years
Malone et al.
Cancer Res. 2006;66:8297-8308.
ABSTRACT
| FULL TEXT
Genetics, Epidemiology, and Cancer Disparities: Is it Black and White?
Rebbeck et al.
JCO 2006;24:2164-2169.
ABSTRACT
| FULL TEXT
Disparities in Genetic Testing: Thinking Outside the BRCA Box
Hall and Olopade
JCO 2006;24:2197-2203.
ABSTRACT
| FULL TEXT
Characterization of BRCA1 and BRCA2 Mutations in a Large United States Sample
Chen et al.
JCO 2006;24:863-871.
ABSTRACT
| FULL TEXT
|
